Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma

This study has been completed.
Sponsor:
Information provided by:
Angiochem Inc
ClinicalTrials.gov Identifier:
NCT00539344
First received: October 2, 2007
Last updated: July 30, 2014
Last verified: July 2014